Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NAC Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

NCT00453180
View directory record Official record
Conditions
Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 15, 2026, 10:45 AM EDT
Suspended Not applicable Interventional

Mucomyst for Hepatitis C

NCT00493610
View directory record Official record
Conditions
Hepatitis C
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

NCT03757585
View directory record Official record
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling

NCT00273702
View directory record Official record
Conditions
Pathological Gambling
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2007 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of NAC in Alleviation of Hangover Symptoms

NCT02541422
View directory record Official record
Conditions
Hangover Symptoms, NAC
Interventions
N Acetyl Cysteine, placebo
Dietary Supplement · Other
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Personalis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1

NCT04481035
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Adolescent Alcohol Use Disorder

NCT03707951
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
N-acetylcysteine, Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 25 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Not applicable Interventional

N-acetylcysteine in Liver Transplantation

NCT00736541
View directory record Official record
Conditions
End Stage Liver Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
Ibtesam Hilmi
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

NCT02259595
View directory record Official record
Conditions
Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss
Interventions
HPN-07, NAC, Placebo
Drug
Lead sponsor
Otologic Pharmaceutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Not applicable Interventional

Treatment Resistant Epilepsy and N-Acetyl Cysteine

NCT02054949
View directory record Official record
Conditions
Autistic Disorder, Seizures, Irritability
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional Results available

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

NCT04545008
View directory record Official record
Conditions
Covid19
Interventions
Famotidine, N-Acetyl cysteine
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Easley, South Carolina • Greenville, South Carolina • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional Results available

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

NCT00896025
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

NCT02583672
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Not applicable Interventional

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

NCT00498342
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)

NCT00724594
View directory record Official record
Conditions
Chorioamnionitis, Brain Injury
Interventions
N-acetylcysteine, Control
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

N-Acetylcysteine for Youth Cannabis Use Disorder

NCT03055377
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
N-acetyl cysteine, Placebo oral capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
14 Years to 21 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Pediatric Trichotillomania

NCT00993265
View directory record Official record
Conditions
Trichotillomania, Hair Pulling
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

NCT04627922
View directory record Official record
Conditions
Cannabis Use, Tobacco Use Disorder, Drug Use Disorder
Interventions
N-Acetyl cysteine, Placebo comparator, Cognitive behavioral therapy (CBT)
Drug · Other · Behavioral
Lead sponsor
Ellen Herbst
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Not applicable Interventional

OA for Breast Cancer NAC Response

NCT05337280
View directory record Official record
Conditions
Breast Cancer
Interventions
Imagio OA/US
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

NCT05177796
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 15, 2026, 10:45 AM EDT